Our studies in melanoma tumors suggested that BRAF/VEGFA targeting reshaped the TME, leading to an improvement of anti‐PD‐1 effectiveness and inducing an immunologic memory response able to reject a second tumor. Here, PDCD1 is linked to melanoma.